Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods - United States, April 2020-June 2022
Overview
Authors
Affiliations
The risk for COVID-19-associated mortality increases with age, disability, and underlying medical conditions (1). Early in the emergence of the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, mortality among hospitalized COVID-19 patients was lower than that during previous pandemic peaks (2-5), and some health authorities reported that a substantial proportion of COVID-19 hospitalizations were not primarily for COVID-19-related illness,* which might account for the lower mortality among hospitalized patients. Using a large hospital administrative database, CDC assessed in-hospital mortality risk overall and by demographic and clinical characteristics during the Delta (July-October 2021), early Omicron (January-March 2022), and later Omicron (April-June 2022) variant periods among patients hospitalized primarily for COVID-19. Model-estimated adjusted mortality risk differences (aMRDs) (measures of absolute risk) and adjusted mortality risk ratios (aMRRs) (measures of relative risk) for in-hospital death were calculated comparing the early and later Omicron periods with the Delta period. Crude mortality risk (cMR) (deaths per 100 patients hospitalized primarily for COVID-19) was lower during the early Omicron (13.1) and later Omicron (4.9) periods than during the Delta (15.1) period (p<0.001). Adjusted mortality risk was lower during the Omicron periods than during the Delta period for patients aged ≥18 years, males and females, all racial and ethnic groups, persons with and without disabilities, and those with one or more underlying medical conditions, as indicated by significant aMRDs and aMRRs (p<0.05). During the later Omicron period, 81.9% of in-hospital deaths occurred among adults aged ≥65 years and 73.4% occurred among persons with three or more underlying medical conditions. Vaccination, early treatment, and appropriate nonpharmaceutical interventions remain important public health priorities for preventing COVID-19 deaths, especially among persons most at risk.
Age-associated differences in mucosal and systemic host responses to SARS-CoV-2 infection.
Hurst J, Mohan A, Dalapati T, George I, Aquino J, Lugo D Nat Commun. 2025; 16(1):2383.
PMID: 40064870 PMC: 11894178. DOI: 10.1038/s41467-025-57655-3.
Impact of COVID-19 on a medium-sized travel medicine clinic in eastern Pennsylvania, USA.
Palwai P, Gareca M, Rao S, Knouse M Trop Dis Travel Med Vaccines. 2025; 11(1):5.
PMID: 40022266 PMC: 11871799. DOI: 10.1186/s40794-024-00239-8.
Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants.
Rodriguez L, Zamora J, Han D, Moshiri J, Peinovich N, Martinez C Viruses. 2025; 17(2).
PMID: 40006923 PMC: 11860839. DOI: 10.3390/v17020168.
Van Eijndhoven D, Vos R, Bos S Transpl Int. 2025; 38:13800.
PMID: 39995815 PMC: 11849561. DOI: 10.3389/ti.2025.13800.
Ramos-Rincon J, Sanchez-Paya J, Gonzalez-De-La-Aleja P, Rodriguez-Diaz J, Merino E Front Public Health. 2025; 13:1488283.
PMID: 39980912 PMC: 11841506. DOI: 10.3389/fpubh.2025.1488283.